Search
for
Sort by
Research 31–60 of 1000+
- An autosomal recessive nonsense variant in the EGFR gene induces perinatal lethality in “Blonde d'Aquitaine” calves
- Erosive pustular dermatosis of the scalp due to EGFR inhibitors: A multicentric study by EADV task force of ‘Dermatology for Cancer Patients’
- 566 Staphylococcus epidermidis for the topical treatment of epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity
- 129 Targeted inhibition of EGFR reduces anti-microbial defense mechanisms at the hair canal
- 176 Hair eruption initiates adverse events of EGFR-targeted cancer therapy
- Scarring hair follicle destruction is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- 785 Single-cell transcriptomic profile of EGFR-deficient epidermal compartments during folliculitis
- 1030 EGFR protects the upper hair follicle from staphylococcus driven folliculitis
- 308 Epidermal keratinocytes regulate bacterial immune responses and host defense through EGFR
- EGFR: stopping stathmin to start the cycle
- Effects of Fumai Paste on EGFR of Skin in Vinorelbine-induced Extravasation Injury Model Rats
- Abstract 1219: Defective catagen entry in EGFR deficient skin precedes cutaneous inflammation
- Expression of EGF and EGFR in Developing Skin of the Goat Fetus
- Expression Characteristics of EGF and EGFR in Developing Skin of Goat Fetus
- Papulopustular eruptions associated with EGFR-pathway-related targeted therapies: clinical spectrum, evidence boundaries, folliculocentric inflammation, and management considerations
- Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment
- PRIDE Complex (Papulopustules and/or Paronychia, Regulatory Abnormalities of Hair Growth, Itching, Dryness Due to EGFR Inhibitors)
- Dermatologic adverse events in EGFR-TKIs: A real-world analysis.
- 59 Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- Folliculitis Decalvans-like Alopecia During Treatment With EGFR Inhibitors for Lung Cancer: A Case Series of 6 Patients
- Síndrome PRIDE: una práctica forma de identificar los efectos adversos cutáneos de los inhibidores del EGFR
- 422 Human hair follicles express PD-L1, whose expression is down-regulated by EGFR and MEK inhibitors ex vivo. A potential mechanism for EGFR inhibitor induced sterile folliculitis
- 870 Y27632 promotes proliferation via EGFR signaling in a newly isolated and characterized human primary sebocyte cell line
- MARIO LACOUTURE: How Do I Treat a Patient with Dermatologic Toxicities to EGFR Inhibitors?
- Effets secondaires cutanéo-muqueux des nouvelles molécules anticancéreuses: Inhibiteurs de l'EGF-R, inhibiteurs de tyrosine kinase et stabilisateurs du fuseau mitotique
- Abnormal hair growth in patients (pts) with metastatic colorectal cancer (mCRC) treated with the anti-epidermal growth factor receptor (EGFr) monoclonal antibody (mAb) panitumumab (Pmab)
- 861 EGFR/MEK inhibitor therapy induces partial hair follicle immune privilege collapse in vivo and ex vivo
- The patient outcomes with EGFR-mutated advanced non-small-cell lung cancer receiving aumolertinib as first-line treatment.
- Molecular Docking Studies and ADME Prediction of Novel Isatin Analogs with Potent Anti-EGFR Activity
- Histopathological Correlates of NAFLD in PCOS: Correlation with Serum Creatinine, eGFR, and Urinary Albumin Levels